Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)

Thomas Benfield; Mika Rämet; Piero Valentini; Ilkka Seppä; Ron Dagan; Peter Richmond; Swati Mercer; Clay Churchill; Robert Lupinacci; Richard McFetridge; Jun Park; Frederick Wittke; Natalie Banniettis; Luwy Musey; Kara Bickham; Janusz Kaminski

doi:10.1016/j.vaccine.2023.02.041

Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)

Thomas Benfield, Mika Rämet, Piero Valentini, Ilkka Seppä, Ron Dagan, Peter Richmond, Swati Mercer, Clay Churchill, Robert Lupinacci, Richard McFetridge, Jun Park, Frederick Wittke, Natalie Banniettis, Luwy Musey, Kara Bickham, Janusz Kaminski

Faculty of Health Sciences

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Background: This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in healthy infants. V114 contains all 13 serotypes in PCV13 and additional serotypes 22F and 33F. Methods: Healthy infants were randomized to two primary doses and one toddler dose (2+1 regimen) of V114 or PCV13 at 3, 5, and 12 months of age; diphtheria, tetanus, pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib), hepatitis B (HepB) vaccine was administered concomitantly. Adverse events (AEs) were collected on Days 1–14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-primary series, immediately prior to toddler dose, and 30 days post-toddler dose. Primary objectives included non-inferiority of V114 to PCV13 for 13 shared serotypes and superiority of V114 to PCV13 for serotypes 22F and 33F. Results: 1191 healthy infants were randomized to V114 (n = 595) or PCV13 (n = 596). Proportions of participants with solicited AEs and serious AEs were comparable between groups. V114 met non-inferiority criteria for 13 shared serotypes, based on difference in proportions with serotype-specific IgG ≥0.35 μg/mL (lower bound of two-sided 95% confidence interval [CI] >−10.0) and IgG geometric mean concentration (GMC) ratios (lower bound of two-sided 95% CI >0.5) at 30 days post-toddler dose. V114 met superiority criteria for serotypes 22F and 33F, based on response rates (lower bound of two-sided 95% CI >10.0) and IgG GMC ratios (lower bound of two-sided 95% CI >2.0) at 30 days post-toddler dose. Antibody responses to DTaP-IPV-Hib-HepB met non-inferiority criteria, based on antigen-specific response rates. Conclusion: A two-dose primary series plus toddler dose of V114 was well-tolerated in healthy infants. Compared with PCV13, V114 provided non-inferior immune responses to 13 shared serotypes and superior immune responses to additional serotypes 22F and 33F.

Original language	English
Pages (from-to)	2456-2465
Number of pages	10
Journal	Vaccine
Volume	41
Issue number	15
DOIs	https://doi.org/10.1016/j.vaccine.2023.02.041
State	Published - 6 Apr 2023

Keywords

Child
Clinical trial
Infant
Pneumococcal infections
Pneumococcal vaccines

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2023.02.041

Cite this

Benfield, T., Rämet, M., Valentini, P., Seppä, I., Dagan, R., Richmond, P., Mercer, S., Churchill, C., Lupinacci, R., McFetridge, R., Park, J., Wittke, F., Banniettis, N., Musey, L., Bickham, K., & Kaminski, J. (2023). Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2). Vaccine, 41(15), 2456-2465. https://doi.org/10.1016/j.vaccine.2023.02.041

@article{2bc7bd3c6b4f4d8fad830da2f7ace31d,

title = "Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)",

abstract = "Background: This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in healthy infants. V114 contains all 13 serotypes in PCV13 and additional serotypes 22F and 33F. Methods: Healthy infants were randomized to two primary doses and one toddler dose (2+1 regimen) of V114 or PCV13 at 3, 5, and 12 months of age; diphtheria, tetanus, pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib), hepatitis B (HepB) vaccine was administered concomitantly. Adverse events (AEs) were collected on Days 1–14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-primary series, immediately prior to toddler dose, and 30 days post-toddler dose. Primary objectives included non-inferiority of V114 to PCV13 for 13 shared serotypes and superiority of V114 to PCV13 for serotypes 22F and 33F. Results: 1191 healthy infants were randomized to V114 (n = 595) or PCV13 (n = 596). Proportions of participants with solicited AEs and serious AEs were comparable between groups. V114 met non-inferiority criteria for 13 shared serotypes, based on difference in proportions with serotype-specific IgG ≥0.35 μg/mL (lower bound of two-sided 95% confidence interval [CI] >−10.0) and IgG geometric mean concentration (GMC) ratios (lower bound of two-sided 95% CI >0.5) at 30 days post-toddler dose. V114 met superiority criteria for serotypes 22F and 33F, based on response rates (lower bound of two-sided 95% CI >10.0) and IgG GMC ratios (lower bound of two-sided 95% CI >2.0) at 30 days post-toddler dose. Antibody responses to DTaP-IPV-Hib-HepB met non-inferiority criteria, based on antigen-specific response rates. Conclusion: A two-dose primary series plus toddler dose of V114 was well-tolerated in healthy infants. Compared with PCV13, V114 provided non-inferior immune responses to 13 shared serotypes and superior immune responses to additional serotypes 22F and 33F.",

keywords = "Child, Clinical trial, Infant, Pneumococcal infections, Pneumococcal vaccines",

author = "Thomas Benfield and Mika R{\"a}met and Piero Valentini and Ilkka Sepp{\"a} and Ron Dagan and Peter Richmond and Swati Mercer and Clay Churchill and Robert Lupinacci and Richard McFetridge and Jun Park and Frederick Wittke and Natalie Banniettis and Luwy Musey and Kara Bickham and Janusz Kaminski",

note = "Publisher Copyright: {\textcopyright} 2023 Merck Sharp & Dohme LLC",

year = "2023",

month = apr,

day = "6",

doi = "10.1016/j.vaccine.2023.02.041",

language = "English",

volume = "41",

pages = "2456--2465",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "15",

}

Benfield, T, Rämet, M, Valentini, P, Seppä, I, Dagan, R, Richmond, P, Mercer, S, Churchill, C, Lupinacci, R, McFetridge, R, Park, J, Wittke, F, Banniettis, N, Musey, L, Bickham, K & Kaminski, J 2023, 'Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)', Vaccine, vol. 41, no. 15, pp. 2456-2465. https://doi.org/10.1016/j.vaccine.2023.02.041

TY - JOUR

T1 - Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants

T2 - A phase III study (PNEU-PED-EU-2)

AU - Benfield, Thomas

AU - Rämet, Mika

AU - Valentini, Piero

AU - Seppä, Ilkka

AU - Dagan, Ron

AU - Richmond, Peter

AU - Mercer, Swati

AU - Churchill, Clay

AU - Lupinacci, Robert

AU - McFetridge, Richard

AU - Park, Jun

AU - Wittke, Frederick

AU - Banniettis, Natalie

AU - Musey, Luwy

AU - Bickham, Kara

AU - Kaminski, Janusz

PY - 2023/4/6

Y1 - 2023/4/6

N2 - Background: This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in healthy infants. V114 contains all 13 serotypes in PCV13 and additional serotypes 22F and 33F. Methods: Healthy infants were randomized to two primary doses and one toddler dose (2+1 regimen) of V114 or PCV13 at 3, 5, and 12 months of age; diphtheria, tetanus, pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib), hepatitis B (HepB) vaccine was administered concomitantly. Adverse events (AEs) were collected on Days 1–14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-primary series, immediately prior to toddler dose, and 30 days post-toddler dose. Primary objectives included non-inferiority of V114 to PCV13 for 13 shared serotypes and superiority of V114 to PCV13 for serotypes 22F and 33F. Results: 1191 healthy infants were randomized to V114 (n = 595) or PCV13 (n = 596). Proportions of participants with solicited AEs and serious AEs were comparable between groups. V114 met non-inferiority criteria for 13 shared serotypes, based on difference in proportions with serotype-specific IgG ≥0.35 μg/mL (lower bound of two-sided 95% confidence interval [CI] >−10.0) and IgG geometric mean concentration (GMC) ratios (lower bound of two-sided 95% CI >0.5) at 30 days post-toddler dose. V114 met superiority criteria for serotypes 22F and 33F, based on response rates (lower bound of two-sided 95% CI >10.0) and IgG GMC ratios (lower bound of two-sided 95% CI >2.0) at 30 days post-toddler dose. Antibody responses to DTaP-IPV-Hib-HepB met non-inferiority criteria, based on antigen-specific response rates. Conclusion: A two-dose primary series plus toddler dose of V114 was well-tolerated in healthy infants. Compared with PCV13, V114 provided non-inferior immune responses to 13 shared serotypes and superior immune responses to additional serotypes 22F and 33F.

AB - Background: This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in healthy infants. V114 contains all 13 serotypes in PCV13 and additional serotypes 22F and 33F. Methods: Healthy infants were randomized to two primary doses and one toddler dose (2+1 regimen) of V114 or PCV13 at 3, 5, and 12 months of age; diphtheria, tetanus, pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib), hepatitis B (HepB) vaccine was administered concomitantly. Adverse events (AEs) were collected on Days 1–14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-primary series, immediately prior to toddler dose, and 30 days post-toddler dose. Primary objectives included non-inferiority of V114 to PCV13 for 13 shared serotypes and superiority of V114 to PCV13 for serotypes 22F and 33F. Results: 1191 healthy infants were randomized to V114 (n = 595) or PCV13 (n = 596). Proportions of participants with solicited AEs and serious AEs were comparable between groups. V114 met non-inferiority criteria for 13 shared serotypes, based on difference in proportions with serotype-specific IgG ≥0.35 μg/mL (lower bound of two-sided 95% confidence interval [CI] >−10.0) and IgG geometric mean concentration (GMC) ratios (lower bound of two-sided 95% CI >0.5) at 30 days post-toddler dose. V114 met superiority criteria for serotypes 22F and 33F, based on response rates (lower bound of two-sided 95% CI >10.0) and IgG GMC ratios (lower bound of two-sided 95% CI >2.0) at 30 days post-toddler dose. Antibody responses to DTaP-IPV-Hib-HepB met non-inferiority criteria, based on antigen-specific response rates. Conclusion: A two-dose primary series plus toddler dose of V114 was well-tolerated in healthy infants. Compared with PCV13, V114 provided non-inferior immune responses to 13 shared serotypes and superior immune responses to additional serotypes 22F and 33F.

KW - Child

KW - Clinical trial

KW - Infant

KW - Pneumococcal infections

KW - Pneumococcal vaccines

UR - http://www.scopus.com/inward/record.url?scp=85149963824&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2023.02.041

DO - 10.1016/j.vaccine.2023.02.041

M3 - Article

C2 - 36841723

AN - SCOPUS:85149963824

SN - 0264-410X

VL - 41

SP - 2456

EP - 2465

JO - Vaccine

JF - Vaccine

IS - 15

ER -

Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this